Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/11/2025

Duration of Lyme PCR Positivity After Treatment

Understanding PCR Positivity After Treatment

  • PCR detects bacterial DNA, which can persist after antibiotic treatment even when viable organisms have been eliminated 3
  • Animal studies show that a substantial proportion of successfully treated animals remain PCR positive in some studies, despite being culture negative (culture being the gold standard for determining viability) 3
  • PCR positivity should not be construed to indicate persistence of viable B. burgdorferi unless proven otherwise by culture 3

Clinical Interpretation of Persistent PCR Positivity

  • According to IDSA guidelines, PCR positivity alone after treatment should not be interpreted as evidence of ongoing infection without corresponding clinical symptoms and other supporting evidence 2, 3
  • PCR has not been standardized for routine diagnosis of Lyme disease and should be interpreted in clinical context 4
  • Continued PCR positivity after treatment is not necessarily associated with treatment failure when patients show clinical improvement 3

Antibody Persistence vs. PCR Positivity

  • Antibodies to B. burgdorferi often persist for months or years after successfully treated infection and should not be confused with PCR positivity 4
  • Neither positive serologic test results nor a history of previous Lyme disease ensures that a person has protective immunity 4

Clinical Implications

  • PCR should not be used alone to determine treatment success or failure 1, 3
  • Most patients with early Lyme disease respond well to appropriate antibiotic therapy, with treatment failure rates of approximately 1% 5

Monitoring After Treatment

  • Culture remains the gold standard for determining viability of B. burgdorferi, but is not routinely available in clinical practice 3
  • Clinical response should be the primary determinant of treatment success 2, 5